method
develop
detect
quantit
hadv
human
adenoviru
hbov
human
bocaviru
base
duplex
realtim
pcr
ab
pcr
use
smartcycl
instrument
control
realtim
pcr
carri
albumin
dna
standardis
nonhomogen
respiratori
sampl
crossreact
observ
virus
bacteria
could
found
respiratori
tract
diagnosi
rate
use
ab
pcr
clinic
sampl
hbov
detect
hadv
detect
doubl
detect
hbovhadv
clinic
epidemiolog
characterist
hadvand
hbovinfect
patient
evalu
hadvposit
group
hbovposit
group
sampl
classifi
accord
sever
diseas
hadv
viral
load
appear
link
sever
diseas
convers
differ
two
hbov
group
sever
nonsever
signific
statist
comparison
base
viral
load
p
adjust
viral
load
number
cell
sampl
p
adenovirus
hadv
common
infecti
agent
caus
sporad
epidem
respiratori
infect
mitchel
et
al
date
differ
hadv
serotyp
divid
six
speci
f
identifi
de
jong
et
al
xu
et
al
adenoviru
serotyp
speci
c
ad
serotyp
speci
ad
serotyp
speci
e
frequent
isol
patient
respiratori
tract
diseas
vabret
et
al
accord
world
health
organ
studi
hadv
respiratori
infect
caus
erdman
et
al
immunofluoresc
assay
enzymelink
immunosorb
assay
elisa
viral
isol
techniqu
use
routin
detect
hadv
associ
respiratori
infect
howev
hadv
take
sever
day
grow
cell
cultur
suscept
specimen
toxic
outcompet
bacteria
fungi
diagnosi
viru
isol
rapid
enough
direct
antigen
detect
immunofluoresc
lack
sensit
contrast
molecular
identif
pcr
rapid
sensit
pcr
assay
detect
sequenc
hexon
gene
allard
et
al
hierholz
et
al
morri
et
al
rati
et
al
wherea
pcr
assay
use
sequenc
va
rna
gene
kidd
et
al
vabret
et
al
human
bocaviru
hbov
isol
respiratori
sampl
larg
scale
molecular
viru
screen
alland
et
al
incid
hbov
detect
patient
respiratori
tract
infect
vari
depend
studi
design
alland
arden
et
al
arnold
et
al
et
al
man
et
al
qu
et
al
sloot
et
al
smut
hardi
weissbrich
et
al
hadv
hbov
dna
virus
associ
respiratori
infect
would
conveni
assay
detect
virus
dna
sampl
toward
end
duplex
realtim
pcr
assay
develop
valid
rapid
screen
hadv
hbov
respiratori
sampl
respiratori
sampl
n
collect
patient
hospit
respiratori
symptom
univers
hospit
caen
five
region
hospit
argentan
avranch
cherbourg
fler
vire
januari
februari
patient
rang
day
old
averag
age
median
age
age
distribut
sampl
popul
follow
patient
year
old
patient
year
old
patient
year
old
patient
year
old
patient
year
old
portion
respiratori
sampl
immedi
process
use
convent
viru
detect
method
see
remaind
sampl
frozen
c
test
retrospect
duplex
realtim
adenovirusbocaviru
pcr
ab
pcr
assay
patient
posit
adenoviru
orand
bocaviru
ab
pcr
retrospect
examin
medic
record
conduct
respiratori
diseas
classifi
follow
upper
respiratori
tract
ill
lower
respiratori
tract
ill
without
wheez
bronchiol
exacerb
asthma
case
associ
gastroenter
also
record
convent
method
use
assess
accuraci
ab
pcr
techniqu
hadv
direct
immunofluoresc
assay
dfa
imagen
tm
oxoid
franc
cell
cultur
isol
use
cell
use
detect
respiratori
virus
includ
hadv
previous
describ
freymuth
et
al
pcr
adenoviru
consensu
assay
argen
franc
use
determin
hadv
speci
confirm
adenovirusposit
sampl
detect
direct
immunofluoresc
assay
dfa
cell
cultur
ab
pcr
qualit
pcr
method
previous
describ
alland
et
al
use
routin
detect
hbov
nucleic
acid
extract
l
nasal
sampl
use
magattract
dna
mini
kit
qiagen
courtaboeuf
franc
biorobot
qiagen
elut
l
tri
elut
buffer
te
accord
manufactur
protocol
dna
extract
store
c
use
primer
probe
quantit
realtim
ab
pcr
design
take
account
variabl
adenovirus
report
sequenc
hbov
compat
primer
reaction
system
use
program
v
primer
probe
specif
hadv
select
target
hexon
gene
specif
hbov
target
ns
gene
name
sequenc
primer
probe
follow
caccagccgcaccgcggcgtcatcga
hadv
bocavsj
bocavask
bocap
hexcactgccata
ttatagttgggggag
hbov
dna
extract
l
ad
l
pcr
mixtur
contain
l
primer
l
taqman
probe
l
qiagen
buffer
l
mm
dntp
l
mm
mgcl
unit
hotstart
taq
dna
polymeras
reaction
consist
activ
step
hotstart
taq
dna
polymeras
c
follow
cycl
amplif
includ
c
c
c
fluoresc
data
collect
c
step
reaction
data
acquisit
analys
perform
use
smart
cycler
instrument
il
franc
two
plasmid
construct
hadv
plasmid
contain
nucleotid
sequenc
prototyp
strain
atcc
hexon
partial
gene
nt
amplifi
use
primer
ttatgtggtggcgttgccg
hbov
plasmid
contain
ns
partial
gene
nt
amplifi
use
primer
bocavsk
bocavasi
wild
hbov
strain
select
arbitrarili
sequenc
use
construct
bocaviru
plasmid
plasmid
construct
carri
use
topo
xl
ta
clone
kit
follow
manufactur
recommend
invitrogen
franc
albumin
gene
quantifi
dna
extract
nasal
sampl
posit
hadv
hbov
realtim
pcr
perform
use
smart
cycler
instrument
accord
method
describ
previous
laurendeau
et
al
dilut
seri
human
genom
dna
use
standard
human
genom
dna
roch
franc
result
express
number
cell
per
l
respiratori
sampl
take
account
one
cell
contain
two
copi
albumin
gene
analyt
sensit
quantit
duplex
ab
pcr
assay
assess
use
serial
dilut
hadv
hbov
plasmid
serial
dilut
rang
copiesml
test
duplic
mean
cycl
threshold
ct
valu
plot
copi
number
establish
extern
standard
curv
exclud
potenti
preferenti
amplif
either
hadv
hbov
duplex
realtim
ab
pcr
wide
rang
dilut
hbov
hadv
sampl
test
serial
dilut
hbov
plasmid
rang
copiesml
test
presenc
copiesml
dilut
hadv
plasmid
dilut
hadv
plasmid
rang
copiesml
test
presenc
copiesml
dilut
hbov
plasmid
hbov
sensit
ab
pcr
assay
qualit
assay
alland
also
compar
respiratori
sampl
dna
obtain
two
distinct
nasal
aspir
dilut
determin
endpoint
dilut
valu
assay
extract
dna
dilut
dilut
test
parallel
use
qualit
quantit
assay
evalu
intraassay
reproduc
three
replic
four
nasal
aspir
two
posit
hadv
posit
hbov
subject
independ
dna
extract
realtim
pcr
experi
order
estim
interassay
reproduc
dna
extract
amplifi
three
nasal
aspir
duplic
two
distinct
experi
assay
specif
demonstr
use
infecti
agent
hadv
hbov
also
commonli
found
respiratori
tract
capac
ab
pcr
detect
hadv
serotyp
also
test
use
follow
repres
hadv
prototyp
strain
hadv
spa
hadv
hadv
hadv
hadv
spc
hadv
spd
hadv
spe
hadv
spf
intern
control
assay
pcr
inhibit
extract
effici
use
laboratori
kindli
provid
virolog
depart
univers
hospit
marseil
franc
pr
xavier
de
lamballeri
manuscript
submit
assay
consist
ad
phage
viru
clinic
sampl
refer
sampl
water
order
perform
realtim
pcr
detect
phage
use
extract
procedur
realtim
amplif
procedur
taq
dna
polymeras
research
pcr
inhibitor
extract
effici
conduct
neg
sampl
detect
hbov
hadv
duplex
realtim
ab
pcr
still
avail
sampl
test
carri
sampl
qualit
variabl
describ
percentag
quantit
variabl
mean
standard
deviat
viral
load
log
transform
analysi
qualit
quantit
variabl
compar
chisquar
test
student
ttest
respect
epiinfo
program
v
dfr
excel
use
statist
analysi
p
valu
less
consid
statist
signific
detect
limit
ab
pcr
reproduc
copiesml
copiesml
sampl
hadv
hbov
respect
virus
correl
coeffici
repeatedli
slope
amplif
effici
calcul
test
perform
exclud
potenti
preferenti
amplif
either
hadv
hbov
show
low
amount
one
virus
hadv
hbov
detect
duplex
realtim
ab
pcr
would
detect
presenc
high
amount
viru
preferenti
amplif
observ
copiesml
hadv
hbov
detect
attempt
cycl
threshold
ct
sensit
ab
pcr
detect
hbov
respiratori
sampl
compar
sensit
qualit
hbov
pcr
assay
describ
section
result
first
nasal
aspir
hbov
detect
qualit
assay
dilut
ab
pcr
assay
endpoint
dilut
ii
second
nasal
aspir
hbov
detect
nondilut
dna
qualit
assay
ab
pcr
assay
endpoint
dilut
concern
reproduc
ab
pcr
coeffici
variat
mean
cycl
threshold
ct
valu
within
run
rang
hbov
hadv
run
run
coeffici
variat
mean
ct
valu
rang
hbov
hadv
specif
signal
ab
pcr
perform
sampl
posit
follow
virus
influenza
b
c
virus
ifva
ifvb
ifvc
respiratori
syncyti
virus
rsv
human
metapneumoviru
hmpv
parainfluenza
virus
piv
coronaviru
measl
viru
mump
viru
human
rhinoviru
hrv
prototyp
strain
type
echoviru
human
herp
viru
varicellaezost
viru
vzv
cytomegaloviru
cmv
epstein
barr
viru
ebv
human
herp
viru
parvoviru
bk
jc
virus
mycoplasma
pneumonia
chlamydia
pneumonia
haemophilu
influenza
streptococcu
pneumonia
enterococcu
streptococcu
group
staphylococcu
aureu
pseudomona
aeruginosa
contrast
eight
serotyp
repres
seven
speci
adenoviru
amplifi
detect
adenoviru
probe
specimen
collect
posit
respiratori
viru
use
convent
method
follow
virus
identifi
ifva
rsv
hadv
hrv
hmpv
hsv
ifvc
adenovirus
detect
sampl
use
cultur
method
sampl
posit
cell
cultur
neg
direct
immunofluoresc
assay
dfa
posit
hadv
use
method
ab
pcr
detect
adenovirus
sampl
tabl
sampl
neg
dfa
cultur
method
contrast
sampl
adenovirusposit
convent
method
also
posit
ab
pcr
ab
pcr
adenovirusposit
sampl
also
test
use
adenoviru
consensu
pcr
argen
franc
sampl
confirm
posit
type
distribut
follow
hadv
sp
hadv
sp
c
hadv
sp
e
hadv
sp
f
determin
hbov
detect
sampl
total
use
duplex
ab
pcr
tabl
posit
sampl
neg
use
convent
pcr
method
describ
alland
virus
codetect
hadv
case
hrv
rsv
hbov
ifvc
viru
ifva
viru
hmpv
hbov
codetect
virus
case
rsv
ifva
hadv
hmpv
viru
hadv
hbov
codetect
sampl
ab
pcr
hbov
codetect
frequent
virus
hadv
nasal
sampl
posit
hbov
show
coinfect
versu
nasal
sampl
posit
hadv
p
quantit
viral
load
sampl
hadvposit
use
ab
pcr
show
rang
log
mean
log
sd
log
fig
hbovposit
sampl
viral
load
rang
log
mean
log
sd
log
fig
standard
hadv
hbov
quantit
sampl
albumin
gene
quantifi
parallel
hadv
hbov
dna
posit
specimen
expect
number
cell
nasal
aspir
differ
one
sampl
anoth
nasal
sampl
posit
hadv
mean
albumin
gene
copi
number
log
rang
log
sd
log
fig
sampl
posit
hbov
mean
copi
number
log
rang
log
sd
log
fig
number
copi
albumin
gene
proport
number
cell
sampl
hadv
hbov
particl
also
cellassoci
clinic
sampl
thu
result
express
ratio
number
copi
hadv
hbov
number
copi
albumin
gene
allow
compar
result
obtain
differ
nasal
aspir
ensur
number
cell
nasal
sampl
thu
qualiti
sampl
limit
factor
ratio
hadv
copi
albumin
dna
copi
rang
mean
fig
ratio
hbov
copi
rang
mean
ratio
four
sampl
ratio
indic
high
hbov
dna
level
fig
next
hadv
dna
hbov
dna
quantit
accord
sever
diseas
sever
diseas
defin
low
respiratori
symptom
present
nonsever
diseas
defin
presenc
high
respiratori
symptom
hadv
copi
number
rang
log
mean
log
sd
log
severediseas
group
nonsever
diseas
group
hadv
copi
number
rang
log
mean
log
sd
log
mean
number
hadv
copi
compar
two
group
whether
diseas
sever
log
versu
log
ratio
hadv
copi
albumin
dna
copi
rang
mean
patient
sever
diseas
mean
patient
nonsever
diseas
statist
differ
two
group
hbov
copi
number
rang
log
mean
log
sd
log
sever
diseas
group
log
mean
log
sd
log
nonsever
diseas
group
mean
number
hbov
dna
copi
higher
severediseas
group
nonsever
diseas
group
log
versu
log
differ
signific
statist
p
ratio
hbov
copi
albumin
dna
copi
rang
mean
patient
sever
diseas
mean
patient
nonsever
diseas
differ
two
hbovposit
group
sever
nonsever
remain
statist
signific
standardiza
fig
quantif
hbov
posit
ab
pcr
nasal
aspir
sampl
use
realtim
duplex
abpcr
assay
hbov
albumin
dna
tion
viral
load
accord
number
cell
sampl
p
one
old
femal
patient
two
nasal
aspir
avail
interv
viral
load
hbov
first
nasal
aspir
log
dramat
decreas
day
later
viral
load
second
nasal
aspir
reach
log
patient
hospit
pediatr
depart
feed
difficulti
weight
loss
underli
context
bronchiol
diagnos
one
week
first
nasal
aspir
sampl
admiss
viru
detect
convent
method
neg
three
day
later
second
nasal
aspir
perform
symptom
improv
patient
includ
statist
analysi
isol
case
hadv
hbov
codetect
case
hadv
viral
load
high
one
case
log
mild
case
log
low
level
hbov
viral
load
detect
case
log
low
respiratori
symptom
sever
diseas
present
one
case
high
respiratori
symptom
nonsever
diseas
present
case
research
pcr
inhibitor
extract
effici
conduct
neg
sampl
detect
hbov
hadv
duplex
ab
pcr
sampl
test
posit
detect
phage
ct
vari
ct
refer
control
water
extract
phage
conclus
pcr
inhibitor
present
sampl
clinic
epidemiolog
characterist
hadvand
hbovinfect
patient
summar
tabl
age
distribut
hadvor
hbovinfect
patient
follow
year
patient
year
patient
year
patient
year
patient
age
distribut
differ
age
distribut
sampl
patient
hadvand
hbovposit
patient
year
old
clinic
data
avail
hadvand
hbovposit
patient
data
unavail
hadvposit
patient
hbovposit
patient
age
similar
two
group
proport
male
higher
hadv
group
versu
differ
signific
upper
respiratori
tract
infect
common
hadvinfect
patient
hbovinfect
patient
versu
p
contrast
lower
respiratori
tract
infect
frequent
report
hbovinfect
patient
hadvinfect
patient
versu
p
respiratori
distress
exacerb
asthma
frequent
report
hbovposit
patient
hadvposit
patient
versu
respiratori
distress
versu
exacerb
asthma
respect
howev
differ
signific
statist
moreov
patient
hadvposit
group
suffer
lower
respiratori
tract
infect
coinfect
respiratori
virus
respiratori
syncyti
viru
case
hbov
case
hmpv
case
rhinoviru
case
similarli
patient
suffer
lower
respiratori
tract
infect
hbovposit
group
coinfect
virus
rsv
case
hmpv
case
case
rhinoviru
case
hadv
case
fever
report
frequent
hadv
group
hbov
group
versu
p
patient
gastroenter
patient
frequent
hadvposit
hbovposit
versu
ns
detect
rotaviru
stool
report
patient
hadvposit
group
patient
hbovposit
group
data
shown
evid
nosocomi
acquisit
found
hadvposit
old
girl
hospit
pediatr
depart
malnutrit
nasal
aspir
stool
sampl
taken
day
admiss
hadvposit
even
though
left
hospit
hbov
hadv
codetect
numer
sampl
distinct
clinic
evalu
monoinfect
patient
conduct
clinic
epidemiolog
characterist
patient
present
tabl
bronchiti
exacerb
asthma
respiratori
distress
report
frequent
hbovposit
patient
hadvposit
patient
versu
bronchiti
versu
exacerb
asthma
versu
respiratori
distress
differ
statist
signific
case
exacerb
asthma
p
studi
two
object
first
object
develop
realtim
duplex
pcr
method
detect
quantit
hadv
hbov
dna
virus
detect
routin
nasal
aspir
patient
respiratori
symptom
second
object
evalu
clinic
epidemiolog
characterist
hadvand
hbovinfect
patient
sampl
popul
crossreact
respiratori
agent
associ
respiratori
infect
analyt
sensit
good
ie
copiesml
two
virus
thu
duplex
realtim
ab
pcr
conveni
use
altern
method
detect
hadv
hbov
other
also
develop
convent
realtim
pcr
techniqu
detect
hbov
dna
respiratori
sampl
arnold
et
al
choi
et
al
foulongn
et
al
nesk
et
al
simon
et
al
use
method
preval
hbovposit
sampl
patient
respiratori
symptom
usual
use
ab
pcr
preval
hbov
infect
patient
differ
detect
frequenc
hbov
dna
differ
studi
may
explain
patient
characterist
season
geograph
variat
moreov
pcr
method
would
standard
compar
directli
present
studi
sensit
duplex
ab
pcr
greater
convent
pcr
detect
hbov
ab
pcr
detect
hbovposit
nasal
sampl
convent
pcr
exclud
fals
posit
due
crosscontamin
two
complementari
studi
conduct
first
studi
second
round
dna
extract
carri
use
nasal
aspir
sampl
suffici
volum
remain
sampl
confirm
posit
use
second
realtim
pcr
method
carri
differ
laboratori
virolog
st
vincent
de
paul
hospit
pari
second
studi
ab
pcr
convent
pcr
use
test
serial
dilut
two
dna
sampl
extract
posit
nasal
aspir
ab
pcr
greater
sensit
ie
abl
detect
viru
reaction
use
less
dna
need
posit
result
use
convent
pcr
thu
differ
result
use
ab
pcr
versu
convent
pcr
like
due
sampl
low
viral
load
addit
result
test
convent
pcr
follow
nest
pcr
probe
hybrid
also
explain
lower
sensit
convent
pcr
direct
immunofluoresc
assay
dfa
imagen
tm
oxoid
franc
rapid
use
method
clinic
diagnosi
hadv
respiratori
infect
vabret
et
al
howev
due
low
sensit
sampl
neg
hadv
use
direct
immunofluoresc
assay
requir
test
iso
tabl
epidemiolog
clinic
characterist
hadvand
hbovinfect
studi
patient
hadv
group
n
hbov
group
n
pvalu
claa
et
al
damen
et
al
gu
et
al
heim
et
al
mitchel
et
al
gu
et
al
describ
realtim
pcr
method
use
six
differ
primer
set
detect
hadv
speci
heim
et
al
report
broadli
reactiv
hadv
assay
use
quantit
realtim
pcr
consensu
primer
probe
claa
et
al
develop
intern
control
realtim
pcr
assay
detect
quantifi
hadv
serotyp
involv
dissemin
adenoviru
diseas
damen
et
al
describ
recent
intern
control
hadv
realtim
pcr
method
detect
known
hadv
serotyp
use
mix
degener
primer
newli
develop
method
luminex
xtag
respiratori
viru
panel
allow
detect
respiratori
virus
test
like
save
money
time
well
increas
diagnosi
rate
howev
limit
term
viru
quantit
detect
low
viral
load
pabbaraju
et
al
present
studi
diagnosi
rate
use
ab
pcr
assay
clinic
sampl
hbov
detect
hadv
detect
dual
detect
hbovhadv
significantli
higher
diagnosi
rate
use
convent
techniqu
sampl
collect
two
winter
month
januari
februari
aim
document
yearround
chang
preval
duplex
ab
pcr
assay
also
abl
detect
mix
hadvhbov
infect
one
aim
even
though
dual
infect
rare
studi
clinic
implic
coinfect
remain
unclear
concern
quantit
result
present
studi
amount
hadv
posit
nasal
sampl
seem
relat
sever
acut
respiratori
tract
diseas
p
base
hadvalbumin
statist
signific
differ
found
patient
sever
symptom
versu
mild
symptom
sever
diseas
appear
link
hadv
viral
load
convers
amount
hbov
posit
nasal
sampl
relat
sever
symptom
differ
two
hbov
group
sever
nonsever
statist
signific
comparison
base
viral
load
p
adjust
viral
load
number
cell
sampl
p
nevertheless
isol
case
patient
sampl
twice
suggest
hbov
viral
load
link
tabl
epidemiolog
clinic
characterist
hadv
hbov
monoinfect
patient
hadv
group
n
hbov
group
n
b
pvalu
stage
infect
studi
quantit
result
standard
accord
number
cell
nasal
sampl
nevertheless
factor
viral
replic
could
play
role
symptom
sever
inflammatori
respons
genet
suscept
patient
absenc
assay
intern
control
pcr
inhibit
extract
effici
neg
sampl
limit
studi
detect
pcr
inhibitor
consist
supplementari
pcr
assay
increas
cost
research
nevertheless
detect
pcr
inhibitor
import
step
routin
test
studi
nasal
aspir
sampl
show
low
percentag
inhibitor
techniqu
describ
coira
et
al
includ
intern
control
suppli
promega
kit
amplif
inhibitor
detect
clinic
evalu
coira
et
al
coira
et
al
syrmi
et
al
use
endogen
human
retroviru
intern
control
found
sampl
test
amplif
syrmi
et
al
dingl
et
al
creat
stabl
intern
control
base
modifi
rna
fragment
hepat
delta
dingl
et
al
among
respiratori
sampl
test
two
case
inhibit
detect
possibl
dilut
sampl
transport
medium
overcom
effect
inhibitor
syrmi
et
al
limit
clinic
evalu
studi
small
number
patient
includ
miss
clinic
data
due
retrospect
examin
medic
file
short
studi
conclus
sensit
specif
duplex
realtim
pcr
assay
develop
detect
hadv
hbov
dna
respiratori
sampl
studi
need
confirm
result
concern
link
viral
load
sever
diseas
